Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 20/20 | 1.00 |
| ▸ | MMP1 | P03956 | 11/20 | 1.00 |
| ▸ | MMP3 | P08254 | 11/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 9/20 | 1.00 |
| ▸ | ADAM9 | Q13443 | 9/20 | 1.00 |
| ▸ | AREG | P15514 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021367 | 1.00 | MMP9 (1.00) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL10052673 | 0.77 | MMP9 (1.00) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL10021368 | 0.77 | MMP9 (1.00) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL8381087 | 0.74 | MMP3 (0.68) | MMP9MMP1MMP3 | |
| SCHEMBL10021369 | 0.70 | MMP9 (0.78) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL8379816 | 0.66 | MMP3 (0.68) | MMP9MMP1MMP3 | |
| SCHEMBL8384868 | 0.64 | SMN1; SMN2 (0.53) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL8383954 | 0.64 | MMP8 (0.57) | MMP9MMP1MMP3 | |
| SCHEMBL11558987 | 0.63 | MMP9 (0.45) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL11562455 | 0.62 | MMP9 (0.45) | MMP9MMP1MMP3ADAM17ADAM9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | MMP9 631/4885MMP1 1050/4885MMP3 233/4885 |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | OGFR, CSGALNACT1, OPRL1 | MMP9 631/4885MMP1 1050/4885MMP3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.